{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:38:22Z","timestamp":1791041902087,"version":"4.1.0"},"reference-count":177,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Noonan syndrome (NS) is a disorder characterized by a typical facial gestalt, congenital heart defects, variable cognitive deficits, skeletal defects, and short stature. NS is caused by germline pathogenic variants in genes coding proteins with a role in the RAS\/mitogen-activated protein kinase signaling pathway, and it is typically associated with substantial genetic and clinical complexity and variability. Short stature is a cardinal feature in NS, with evidence indicating that growth hormone (GH) deficiency, partial GH insensitivity, and altered response to insulin-like growth factor I (IGF-1) are contributing events for growth failure in these patients. Decreased IGF-I, together with low\/normal responses to GH pharmacological provocation tests, indicating a variable presence of GH deficiency\/resistance, in particular in subjects with pathogenic <jats:italic>PTPN11<\/jats:italic> variants, are frequently reported. Nonetheless, short- and long-term studies have demonstrated a consistent and significant increase in height velocity (HV) in NS children and adolescents treated with recombinant human GH (rhGH). While the overall experience with rhGH treatment in NS patients with short stature is reassuring, it is difficult to systematically compare published data due to heterogeneous protocols, potential enrolment bias, the small size of cohorts in many studies, different cohort selection criteria and varying durations of therapy. Furthermore, in most studies, the genetic information is lacking. NS is associated with a higher risk of benign and malignant proliferative disorders and hypertrophic cardiomyopathy, and rhGH treatment may further increase risk in these patients, especially as dosages vary widely. Herein we provide an updated review of aspects related to growth, altered function of the GH\/IGF axis and cell response to GH\/IGF stimulation, rhGH treatment and its possible adverse events. Given the clinical variability and genetic heterogeneity of NS, treatment with rhGH should be personalized and a conservative approach with judicious surveillance is recommended. Depending on the genotype, an individualized follow-up and close monitoring during rhGH treatments, also focusing on screening for neoplasms, should be considered.<\/jats:p>","DOI":"10.3389\/fendo.2022.951331","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T09:15:56Z","timestamp":1660814156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Inside the Noonan \u201cuniverse\u201d: Literature review on growth, GH\/IGF axis and rhGH treatment: Facts and concerns"],"prefix":"10.3389","volume":"13","author":[{"given":"Stefano","family":"Stagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Priolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":". Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2017.249","article-title":"Autosomal recessive noonan syndrome associated with biallelic LZTR1 variants","volume":"20","author":"Johnston","year":"2018","journal-title":"Genet Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2021.09.007","article-title":"SPRED2 loss-of-function causes a recessive noonan syndrome-like phenotype","volume":"108","author":"Motta","year":"2021","journal-title":"Am J Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1968.02100020377005","article-title":"Hypertelorism with turner phenotype. a new syndrome with associated congenital heart disease","volume":"116","author":"Noonan","year":"1968","journal-title":"Am J Dis Child"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-006-9021-1","article-title":"Noonan syndrome and related disorders: alterations in growth and puberty","volume":"7","author":"Noonan","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2010.09.002","article-title":"Noonan syndrome and clinically related disorders","volume":"25","author":"Tartaglia","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/genes10080580","article-title":"Clinical and genetic findings in children with neurofibromatosis type 1, legius syndrome, and other related neurocutaneous disorders","volume":"10","author":"Giugliano","year":"2019","journal-title":"Genes (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"61.e1","DOI":"10.1016\/j.anpedi.2020.04.008","article-title":"[Noonan syndrome: genetic and clinical update and treatment options]","volume":"93","author":"Carcavilla","year":"2020","journal-title":"Pediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2021.06.004","article-title":"RASopathies: from germline mutations to somatic and multigenic diseases","volume":"44","author":"Riller","year":"2021","journal-title":"BioMed J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s42003-021-02149-3","article-title":"Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line","volume":"4","author":"Pudewell","year":"2021","journal-title":"Commun Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2010.06.015","article-title":"Heterozygous germline mutations in the CBL tumor-suppressor gene cause a noonan syndrome-like phenotype","volume":"87","author":"Martinelli","year":"2010","journal-title":"Am J Hum Genet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ajhg.2020.06.018","article-title":"Enhanced MAPK1 function causes a neurodevelopmental disorder within the RASopathy clinical spectrum","volume":"107","author":"Motta","year":"2020","journal-title":"Am J Hum Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2010.05790.x","article-title":"Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms","volume":"1214","author":"Tartaglia","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1210\/er.2017-00232","article-title":"The RASopathy family: Consequences of germline activation of the RAS\/MAPK pathway","volume":"39","author":"Tajan","year":"2018","journal-title":"Endocr Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy412","article-title":"Dominant noonan syndrome-causing LZTR1 mutations specifically affect the kelch domain substrate-recognition surface and enhance RAS-MAPK signaling","volume":"28","author":"Motta","year":"2019","journal-title":"Hum Mol Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2019.00220","article-title":"Correlation between genetic heterogeneity and variability for response to growth hormone in noonan syndrome","volume":"62","author":"Shin","year":"2019","journal-title":"Korean J Pediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.691240","article-title":"Etiology and treatment of growth delay in noonan syndrome","volume":"12","author":"Rodr\u00edguez","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030754","article-title":"Feeding problems in patients with noonan syndrome: A narrative review","volume":"11","author":"Tiemens","year":"2022","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000243776","article-title":"Growth in noonan syndrome","author":"Otten","year":"2009","journal-title":"Horm Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0995","article-title":"PTPN11 mutations are associated with mild growth hormone resistance in individuals with noonan syndrome","volume":"90","author":"Binder","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajmg.a.20502","article-title":"Adult height in noonan syndrome","author":"Noonan","year":"2003","journal-title":"Am J Med Genet A"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38649","article-title":"First-year growth in children with noonan syndrome: Associated with feeding problems","volume":"176","author":"Croonen","year":"2018","journal-title":"Am J Med Genet A"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0922","article-title":"Growth patterns of patients with noonan syndrome: correlation with age and genotype","volume":"174","author":"Cessans","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ppedcard.2015.01.002","article-title":"Cardiomyopathies in noonan syndrome and the other RASopathies","volume":"39","author":"Gelb","year":"2015","journal-title":"Prog Pediatr Cardiol"},{"key":"B26","first-page":"1993","article-title":"Noonan syndrome","volume-title":"GeneReviews\u00ae [Internet]","author":"Allanson","year":"2001"},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF03401378","article-title":"Bone status in genetic syndromes: a review","volume":"14","author":"Stagi","year":"2015","journal-title":"Hormones (Athens)"},{"key":"B28","article-title":"Malformacion de Arnold-chiari en el sindrome de noonan y otros sindromes de la via RAS\/MAPK [Arnold-chiari malformation in noonan syndrome and other syndromes of the RAS\/MAPK pathway]","volume":"60","author":"Ejarque","year":"2015","journal-title":"Rev Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-012-2000-9","article-title":"Association between noonan syndrome and chiari I malformation: a case-based update","volume":"29","author":"Keh","year":"2013","journal-title":"Childs Nerv Syst"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.37","article-title":"Cancer risk in patients with noonan syndrome carrying a PTPN11 mutation","volume":"19","author":"Jongmans","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10080582","article-title":"Low-grade gliomas in patients with noonan syndrome: Case-based review of the literature","volume":"10","author":"Lodi","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B32","first-page":"1993","article-title":"Noonan syndrome. In:","volume-title":"GeneReviews\u00ae [Internet]","author":"Roberts","year":"2001"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2008.188","article-title":"Multiple giant cell lesions in patients with noonan syndrome and cardio-facio-cutaneous syndrome","volume":"17","author":"Neumann","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-4","article-title":"Noonan syndrome","volume":"2","author":"van der Burgt","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"B35","unstructured":"Noonan syndrome guideline development group. 2010. management of noonan syndrome. a clinical guideline"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3207","article-title":"Noonan syndrome: clinical features, diagnosis, and management guidelines","volume":"126","author":"Romano","year":"2010","journal-title":"Pediatrics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2018.23.4.176","article-title":"Growth hormone therapy in patients with noonan syndrome","volume":"23","author":"Seo","year":"2018","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.6065\/apem.1938154.077","article-title":"Effectiveness of growth hormone therapy in children with noonan syndrome","volume":"25","author":"Seok","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5571524","article-title":"Lack of catch-up growth with growth hormone treatment in a child born small for gestational age leading to a diagnosis of noonan syndrome with a pathogenic PTPN11 variant","volume":"2021","author":"Olivieri","year":"2021","journal-title":"Case Rep Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35519","article-title":"Growth standards of patients with noonan and noonan-like syndromes with mutations in the RAS\/MAPK pathway","author":"Malaquias","year":"2012","journal-title":"Am J Med Genet A"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000331266","article-title":"RASopathies: Clinical diagnosis in the first year of life","volume":"1","author":"Digilio","year":"2011","journal-title":"Mol Syndromol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000184618","article-title":"Growth hormone treatment in noonan syndrome: report of four cases who reached final height","volume":"44","author":"Municchi","year":"1995","journal-title":"Horm Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-247513","article-title":"High energy expenditure in a patient with feeding problems and noonan syndrome spectrum disorder","volume":"15","author":"Tiemens","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.37639","article-title":"Nutritional aspects of noonan syndrome and noonan-related disorders","volume":"170","author":"da Silva","year":"2016","journal-title":"Am J Med Genet A"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddab270","article-title":"Hyperactive HRAS dysregulates energetic metabolism in fibroblasts from patients with Costello syndrome via enhanced production of reactive oxidizing species","volume":"31","author":"Carpentieri","year":"2022","journal-title":"Hum Mol Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104439","article-title":"Metabolic profiling of Costello syndrome: Insights from a single-center cohort","volume":"65","author":"Leoni","year":"2022","journal-title":"Eur J Med Genet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.11.076","article-title":"Understanding growth failure in Costello syndrome: Increased resting energy expenditure","volume":"170","author":"Leoni","year":"2016","journal-title":"J Pediatr"},{"key":"B48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/MED.0000000000000380","article-title":"Noonan syndrome: an update on growth and development","volume":"25","author":"Yart","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406107111","article-title":"LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity","volume":"111","author":"Tajan","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B50","article-title":"Evaluation of puberty in patients with noonan syndrome and mutations in the RAS\/MAPK genes, in: 58th Annual ESPE Meeting","volume-title":"Horm Res Paediatr","author":"Malaquias","year":"2019"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1038\/s41467-021-21712-4","article-title":"Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans","volume":"12","author":"Gualtieri","year":"2021","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.40432","article-title":"Cleft palate and hypopituitarism in a patient with noonan-like syndrome with loose anagen hair-1","volume":"176","author":"Couser","year":"2018","journal-title":"Am J Med Genet A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(96)70005-7","article-title":"Growth hormone treatment in noonan syndrome: the national cooperative growth study experience","volume":"128","author":"Romano","year":"1996","journal-title":"J Pediatr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.37260","article-title":"Response to long-term growth hormone therapy in patients affected by RASopathies and growth hormone deficiency: Patterns of growth, puberty and final height data","author":"Tamburrino","year":"2015","journal-title":"Am J Med Genet A"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01188.x","article-title":"Growth hormone (GH) secretion in children with noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment","volume":"54","author":"Noordam","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.737893","article-title":"GH responsiveness in children with noonan syndrome compared to turner syndrome","volume":"12","author":"Dahlgren","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000516407","article-title":"Differential diagnosis of the short IGF-I-Deficient child with apparently normal growth hormone secretion","volume":"94","author":"Wit","year":"2021","journal-title":"Horm Res Paediatr"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502231","article-title":"Diagnosis, genetics, and therapy of short stature in children: A growth hormone research society international perspective","volume":"92","author":"Collett-Solberg","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.51.61","article-title":"Clinical evaluation of recombinant human growth hormone in noonan syndrome","volume":"51","author":"Ogawa","year":"2004","journal-title":"Endocr J"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0413","article-title":"Long-term GH treatment improves adult height in children with noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11","volume":"159","author":"Noordam","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2005.tb02081.x","article-title":"Improved final height with long-term growth hormone treatment in noonan syndrome","volume":"94","author":"Osio","year":"2005","journal-title":"Acta Paediatr"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2094","article-title":"Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone","volume":"94","author":"Romano","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/1687-9856-2012-15","article-title":"Effect of 4 years of growth hormone therapy in children with noonan syndrome in the American norditropin studies: Web-enabled research (ANSWER) program registry","volume":"2012","author":"Lee","year":"2012","journal-title":"Int J Pediatr Endocrinol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13052-015-0183-x","article-title":"Five-year response to growth hormone in children with noonan syndrome and growth hormone deficiency","volume":"41","author":"Zavras","year":"2015","journal-title":"Ital J Pediatr"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0313","article-title":"Efficacy and safety of two doses of norditropin\u00ae (somatropin) in short stature due to noonan syndrome: A 2-year randomized, double-blind, multicenter trial in Japanese patients","volume":"65","author":"Ozono","year":"2018","journal-title":"Endocr J"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0371","article-title":"Long-term efficacy and safety of two doses of norditropin\u00ae (somatropin) in noonan syndrome: A 4-year randomized, double-blind, multicenter trial in Japanese patients","volume":"67","author":"Horikawa","year":"2020","journal-title":"Endocr J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1159\/000512429","article-title":"Long-term effectiveness and safety of childhood growth hormone treatment in noonan syndrome","volume":"93","author":"Rohrer","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1991.tb11880.x","article-title":"Noonan's syndrome: Abnormalities of the growth hormone\/IGF-I axis and the response to treatment with human biosynthetic growth hormone","volume":"80","author":"Ahmed","year":"1991","journal-title":"Acta Paediatr Scand"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1993.tb17626.x","article-title":"Long-term treatment with growth hormone in noonan's syndrome","volume":"82","author":"Thomas","year":"1993","journal-title":"Acta Paediatr"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.6.8964866","article-title":"The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with noonan's syndrome","volume":"81","author":"Cotterill","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1997.tb15175.x","article-title":"Growth hormone therapy in pre-pubertal children with noonan syndrome: first year growth response and comparison with turner syndrome","volume":"86","author":"De Schepper","year":"1997","journal-title":"Acta Paediatr"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/BF02731057","article-title":"Defective growth hormone (GH) secretion and short-term treatment in noonan syndrome","volume":"65","author":"Soliman","year":"1998","journal-title":"Indian J Pediatr"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/adc.84.5.440","article-title":"Short stature in noonan syndrome: response to growth hormone therapy","volume":"84","author":"Kirk","year":"2001","journal-title":"Arch Dis Child"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.5.7468","article-title":"Growth hormone therapy and growth in children with noonan's syndrome: results of 3 years' follow-up","volume":"86","author":"MacFarlane","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2559","article-title":"PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with noonan syndrome","volume":"90","author":"Ferreira","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0983","article-title":"Noonan syndrome: relationships between genotype, growth, and growth factors","volume":"91","author":"Limal","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2008.21.3.267","article-title":"Response to growth hormone treatment and final height in noonan syndrome in a large cohort of patients in the KIGS database","volume":"21","author":"Raaijmakers","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1159\/000339677","article-title":"Response to growth hormone therapy in children with noonan syndrome: correlation with or without PTPN11 gene mutation","volume":"77","author":"Choi","year":"2012","journal-title":"Horm Res Paediatr"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.3013","article-title":"The growth characteristics of patients with noonan syndrome: Results of three years of growth hormone treatment: A nationwide multicenter study","volume":"8","author":"\u015e\u0131klar","year":"2016","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2018.06842","article-title":"Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with noonan syndrome","volume":"62","author":"Jo","year":"2019","journal-title":"Korean J Pediatr"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000500264","article-title":"Impact of growth hormone therapy on adult height in patients with PTPN11 mutations related to noonan syndrome","volume":"91","author":"Malaquias","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B82","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000498859","article-title":"Treatment with growth hormone in noonan syndrome observed during 25 years of KIGS: Near adult height and outcome prediction","volume":"91","author":"Ranke","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.107292","article-title":"Effect of growth hormone therapy in patients with noonan syndrome: A retrospective study","volume":"18","author":"Apperley","year":"2020","journal-title":"Int J Endocrinol Metab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.761171","article-title":"Growth in children with noonan syndrome and effects of growth hormone treatment on adult height","volume":"12","author":"Libraro","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000192439","article-title":"Noonan syndrome, the ras-MAPK signalling pathway and short stature","author":"Binder","year":"2009","journal-title":"Horm Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1159\/000243779","article-title":"GH therapy in noonan syndrome: Review of final height data","author":"Dahlgren","year":"2009","journal-title":"Horm Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"26","DOI":"10.6065\/apem.2016.21.1.26","article-title":"Long-term efficacy of recombinant human growth hormone therapy in short-statured patients with noonan syndrome","volume":"21","author":"Jeong","year":"2016","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/BF00441408","article-title":"Noonan syndrome: Growth and clinical manifestations in 144 cases","volume":"148","author":"Ranke","year":"1988","journal-title":"Eur J Pediatr"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1159\/000048101","article-title":"Effects of growth hormone treatment on left ventricular dimensions in children with noonan's syndrome","volume":"56","author":"Noordam","year":"2001","journal-title":"Horm Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2002.15.6.851","article-title":"Growth hormone therapy in noonan's syndrome: non-cardiomyopathic congenital heart disease does not adversely affect growth improvement","volume":"15","author":"Brown","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B91","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000028761","article-title":"A 16-year-old male with noonan's syndrome develops progressive scoliosis and deteriorating gait","volume":"30","author":"Sanford","year":"1999","journal-title":"Pediatr Neurosurg"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s002230010040","article-title":"Estrogen deficiency is a potential cause for osteopenia in adult male patients with noonan's syndrome","volume":"66","author":"Takagi","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.30598","article-title":"Genotypic and phenotypic characterization of noonan syndrome: new data and review of the literature","author":"Jongmans","year":"2005","journal-title":"Am J Med Genet A"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2005.10.003","article-title":"Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors","volume":"166","author":"Martinelli","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-007-0636-3","article-title":"Tumor development in three patients with noonan syndrome","volume":"167","author":"Fryssira","year":"2008","journal-title":"Eur J Pediatr"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31818ab2cf","article-title":"Primary mixed glioneuronal tumor of the central nervous system in a patient with noonan syndrome: a case report and review of the literature","volume":"31","author":"Sherman","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22193","article-title":"Pilocytic astrocytoma in a child with noonan syndrome","volume":"53","author":"Schuettpelz","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"P1356","DOI":"10.1055\/s-0030-1265602","article-title":"Dysembryoplastic neuroepithelial tumor (DNET) in a patient with noonan syndrome","volume":"41","author":"Selter","year":"2010","journal-title":"Neuropediatrics"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrex.2011.01.005","article-title":"Remarkable intra-cerebral lesions on MRI in a patient with noonan syndrome","volume":"78","author":"de Jong","year":"2011","journal-title":"Eur J Radiol Extra"},{"key":"B100","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5414\/np300374","article-title":"Rosette forming glioneuronal tumor in association with noonan syndrome: pathobiological implications","volume":"30","author":"Karafin","year":"2011","journal-title":"Clin Neuropathol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/neuonc\/nos108","article-title":"Dysembyoplastic neuroepithelial tumor in two relatives with noonan syndrome and a PTPN 11 mutation","volume":"14","author":"Bendel","year":"2012","journal-title":"Neuro Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36005","article-title":"Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation","author":"Rankin","year":"2013","journal-title":"Am J Med Genet A"},{"key":"B103","first-page":"94","article-title":"A rare brain tumor in noonan syndrome: Report of two cases, in: 53rd ESPE Meeting","volume-title":"Horm Res Paediatr","author":"Pellegrin","year":"2014"},{"key":"B104","first-page":"73","article-title":"Dysembryoplastic neuroepithelial tumor (DNET) and Noonan syndrome. A case report. In: Abstracts of the XVIII international congress of neuropathology; Rio de Janeiro, brazil. 14\u201318 September 2014","volume":"24","author":"Delisle","year":"2014","journal-title":"Brain Pathol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1159\/000479107","article-title":"Occurrence of cranial neoplasms in pediatric patients with noonan syndrome receiving growth hormone: Is screening with brain MRI prior to initiation of growth hormone indicated","volume":"88","author":"Bangalore Krishna","year":"2017","journal-title":"Horm Res Paediatr"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou073","article-title":"Mutations in PTPN11 gene may predispose to development of midline low grade gliomas.  Abstracts from the 16th international symposium on pediatric neuro-oncology in conjunction with the 8th st. Jude-VIVA forum","volume":"16","author":"Rush","year":"2014","journal-title":"Neuro-Oncology"},{"key":"B107","article-title":"Abstracts from the 16th international symposium on pediatric neuro-oncology in conjunction with the 8th st. Jude-VIVA forum, June 28-July 2, 2014, Singapore","author":"Bendel","year":"2014"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.75","article-title":"Cancer spectrum and frequency among children with noonan, Costello, and cardio-facio-cutaneous syndromes","volume":"112","author":"Kratz","year":"2015","journal-title":"Br J Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25382","article-title":"Optic nerve pilomyxoid astrocytoma in a patient with noonan syndrome","volume":"62","author":"Nair","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ajmg.a.37379","article-title":"Occurrence of DNET and other brain tumors in noonan syndrome warrants caution with growth hormone therapy","author":"McWilliams","year":"2016","journal-title":"Am J Med Genet A"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38108","article-title":"Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature","volume":"173","author":"Siegfried","year":"2017","journal-title":"Am J Med Genet A"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27625","article-title":"Occurrence of high-grade glioma in noonan syndrome: Report of two cases","volume":"66","author":"El-Ayadi","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6091059","article-title":"A first case report of subependymoma in PTPN11 mutation-associated noonan syndrome","volume":"2019","author":"Boonyawat","year":"2019","journal-title":"Case Rep Neurol Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.62178","article-title":"Recurrent ganglioneuroma in PTPN11-associated noonan syndrome: A case report and literature review","volume":"185","author":"Morales-Rosado","year":"2021","journal-title":"Am J Med Genet A"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106725","article-title":"Spinal cord glioblastoma multiforme in a patient with noonan syndrome: A clinical report","volume":"207","author":"Khan","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2007.12.005","article-title":"Germline PTPN11 missense mutation in a case of noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors","volume":"182","author":"Mutesa","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21509","article-title":"Hepatoblastoma in a noonan syndrome patient with a PTPN11 mutation","volume":"50","author":"Yoshida","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-003-1227-6","article-title":"Noonan syndrome with leukaemoid reaction and overproduction of catecholamines: a case report","volume":"162","author":"Kondoh","year":"2003","journal-title":"Eur J Pediatr"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20527","article-title":"Therapy-related acute myeloid leukemia in a child with noonan syndrome and clonal duplication of the germline PTPN11 mutation","volume":"48","author":"Chantrain","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/cge.13588","article-title":"Molecular and phenotypic spectrum of noonan syndrome in Chinese patients","volume":"96","author":"Li","year":"2019","journal-title":"Clin Genet"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2008.00678.x","article-title":"Granular cell tumor of the scrotum in a child with noonan syndrome","volume":"25","author":"Sidwell","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01111.x","article-title":"Multiple granular cell tumors in a child with noonan syndrome","volume":"27","author":"Ramaswamy","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01641.x","article-title":"Atypical granular cell tumor occurring in an individual with noonan syndrome treated with growth hormone","volume":"29","author":"Moos","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1322537","article-title":". Multiple granular cell tumors in a child with noonan syndrome","volume":"23","author":"Bamps","year":"2013","journal-title":"Eur J Pediatr Surg"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13960","article-title":"Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor","volume":"44","author":"Park","year":"2017","journal-title":"J Dermatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33987","article-title":"Co-Occurring SHOC2 and PTPN11 mutations in a patient with severe\/complex noonan syndrome-like phenotype","author":"Ekvall","year":"2011","journal-title":"Am J Med Genet A"},{"key":"B127","doi-asserted-by":"publisher","first-page":"103617","DOI":"10.1016\/j.ejmg.2019.01.007","article-title":"Oligo-astrocytoma in LZTR1-related noonan syndrome","volume":"63","author":"Jacquinet","year":"2020","journal-title":"Eur J Med Genet"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20800","article-title":"A further patient with noonan syndrome due to a SOS1 mutation and rhabdomyosarcoma","volume":"49","author":"Hastings","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20735","article-title":"Tumor spectrum in children with noonan syndrome and SOS1 or RAF1 mutations","volume":"49","author":"Denayer","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"iii471","DOI":"10.1093\/neuonc\/noaa222.850","article-title":"TBIO-27. rasopathies and brain tumorogenesis: are SOS1 mutations concerned","volume":"22","author":"Abdelmoula","year":"2020","journal-title":"Neuro-Oncology"},{"key":"B131","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ajmg.a.61395","article-title":"NRAS associated RASopathy and embryonal rhabdomyosarcoma","volume":"182","author":"Garren","year":"2020","journal-title":"Am J Med Genet A"},{"key":"B132","doi-asserted-by":"crossref","DOI":"10.1038\/ng1641","article-title":"Germline mutations in HRAS proto-oncogene cause Costello syndrome","volume":"37","author":"Aoki","year":"2005","journal-title":"Nat Genet"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.30065","article-title":"Tumor predisposition in Costello syndrome","author":"Gripp","year":"2005","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2005.040352","article-title":"Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases","volume":"43","author":"Kerr","year":"2006","journal-title":"J Med Genet"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2018.12.006","article-title":"Embryonal rhabdomyosarcoma in a patient with a germline CBL pathogenic variant","author":"Ji","year":"2019","journal-title":"Cancer Genet"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38569","article-title":"The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with noonan syndrome, including one with a rare brain tumor","volume":"176","author":"Harms","year":"2018","journal-title":"Am J Med Genet A"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2017.65","article-title":"Genotype and phenotype spectrum of NRAS germline variants","volume":"25","author":"Altm\u00fcller","year":"2017","journal-title":"Eur J Hum Genet"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36375","article-title":"Germline CBL mutation associated with a noonan-like syndrome with primary lymphedema and teratoma associated with acquired uniparental isodisomy of chromosome 11q23","author":"Hanson","year":"2014","journal-title":"Am J Med Genet A"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-015-1627-5","article-title":"Spectrum of mutations and genotype-phenotype analysis in noonan syndrome patients with RIT1 mutations","volume":"135","author":"Yaoita","year":"2016","journal-title":"Hum Genet"},{"key":"B140","doi-asserted-by":"publisher","first-page":"eabe2587","DOI":"10.1126\/scitranslmed.abe2587","article-title":"SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations","volume":"13","author":"Paccoud","year":"2021","journal-title":"Sci Transl Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40659-021-00342-6","article-title":"Molecules linked to ras signaling as therapeutic targets in cardiac pathologies","volume":"54","author":"Ramos-Kuri","year":"2021","journal-title":"Biol Res"},{"key":"B142","article-title":"Signaling pathways mediating the response to hypertrophic stress in the heart","volume":"7","author":"Force","year":"1999","journal-title":"Gene Expr"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000138190.50127.6A","article-title":"Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload","volume":"110","author":"Harris","year":"2004","journal-title":"Circulation"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00512","article-title":"Signaling to cardiac hypertrophy: insights from human and mouse RASopathies","volume":"18","author":"Sala","year":"2012","journal-title":"Mol Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz108","article-title":"Activating MRAS mutations cause noonan syndrome associated with hypertrophic cardiomyopathy","volume":"29","author":"Motta","year":"2020","journal-title":"Hum Mol Genet"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/ng2073","article-title":"Gain-of-function RAF1 mutations cause noonan and LEOPARD syndromes with hypertrophic cardiomyopathy","volume":"39","author":"Pandit","year":"2007","journal-title":"Nat Genet"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/ng2078","article-title":"Germline gain-of-function mutations in RAF1 cause noonan syndrome","volume":"39","author":"Razzaque","year":"2007","journal-title":"Nat Genet"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.32","article-title":"Genotype and phenotype in patients with noonan syndrome and a RIT1 mutation","volume":"18","author":"Kouz","year":"2016","journal-title":"Genet Med"},{"key":"B149","first-page":"1993","article-title":"Noonan syndrome with multiple lentigines","volume-title":"GeneReviews\u00ae [Internet]","author":"Gelb","year":"2007"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.40.6.e74","article-title":"Is growth hormone treatment beneficial or harmful in Costello syndrome","volume":"40","author":"Kerr","year":"2003","journal-title":"J Med Genet"},{"key":"B151","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/cge.13533","article-title":"Delineation of dominant and recessive forms of LZTR1-associated noonan syndrome","volume":"95","author":"Pagnamenta","year":"2019","journal-title":"Clin Genet"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0549","article-title":"Cardiovascular safety of growth hormone treatment in noonan syndrome: real-world evidence","volume":"11","author":"Romano","year":"2022","journal-title":"Endocr Connect"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951110000260","article-title":"Progressively worsening hypertrophic cardiomyopathy in a child with newly diagnosed Costello syndrome while receiving growth hormone therapy","volume":"20","author":"Kobayashi","year":"2010","journal-title":"Cardiol Young"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38854","article-title":"Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients","volume":"176","author":"Levin","year":"2018","journal-title":"Am J Med Genet A"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrcr.2021.06.010","article-title":"Ventricular fibrillation due to a likely pathogenic SOS1 variant: An unrecognized etiology of infantile sudden death","volume":"7","author":"Follansbee","year":"2021","journal-title":"HeartRhythm Case Rep"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951121003310","article-title":"The added value of the electrocardiogram in Noonan syndrome","volume":"32","author":"Vos","year":"2022","journal-title":"Cardiol Young"},{"key":"B157","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000243780","article-title":"Growth hormone and the heart in noonan syndrome","author":"Noordam","year":"2009","journal-title":"Horm Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35639","article-title":"Medical complications, clinical findings, and educational outcomes in adults with noonan syndrome","author":"Smpokou","year":"2012","journal-title":"Am J Med Genet A"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.30300","article-title":"Cancer in noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes","author":"Kratz","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.114595","article-title":"RAS diseases in children","volume":"99","author":"Niemeyer","year":"2014","journal-title":"Haematologica"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1923","article-title":"Activating mutations of the noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia","volume":"64","author":"Bentires-Alj","year":"2004","journal-title":"Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/00062752-200401000-00007","article-title":"SHP-2 and myeloid malignancies","volume":"11","author":"Tartaglia","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666181106100837","article-title":"The landscape of protein tyrosine phosphatase (Shp2) and cancer","volume":"24","author":"Rehman","year":"2018","journal-title":"Curr Pharm Des"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"key":"B165","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.gde.2006.12.011","article-title":"The role of Shp2 (PTPN11) in cancer","volume":"17","author":"Mohi","year":"2007","journal-title":"Curr Opin Genet Dev"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0631","article-title":"Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk","volume":"23","author":"Villani","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B167","article-title":"Ras oncogenes in human cancer: A review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1136\/adc.67.2.178","article-title":"A clinical study of noonan syndrome","volume":"67","author":"Sharland","year":"1992","journal-title":"Arch Dis Child"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-200110000-00006","article-title":"Spinal deformities in noonan syndrome: a clinical review of sixty cases","volume":"83","author":"Lee","year":"2001","journal-title":"J Bone Joint Surg Am"},{"key":"B170","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/BPO.0b013e318220396e","article-title":"Orthopaedic conditions in Ras\/MAPK related disorders","volume":"31","author":"Reinker","year":"2011","journal-title":"J Pediatr Orthop"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27302011000800009","article-title":"Adverse effects of growth hormone replacement therapy in children","volume":"55","author":"Souza","year":"2011","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B172","article-title":"Prevalence and incidence of scoliosis in turner syndrome: a study in 49 girls followed-up for 4 years","volume":"47","author":"Ricotti","year":"2011","journal-title":"Eur J Phys Rehabil Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-05034-2","article-title":"Chiari I malformation in patients with RASopathies","volume":"37","author":"Han","year":"2021","journal-title":"Childs Nerv Syst"},{"key":"B174","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/2011.6.FOCUS11112","article-title":"Associated disorders of chiari type I malformations: a review","volume":"31","author":"Loukas","year":"2011","journal-title":"Neurosurg Focus"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3091","article-title":"An examination of the effects of different doses of recombinant human growth hormone on children with growth hormone deficiency","volume":"11","author":"Xue","year":"2016","journal-title":"Exp Ther Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.5199","article-title":"Association of childhood growth hormone treatment with long-term cardiovascular morbidity","volume":"175","author":"Tidblad","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30163-7","article-title":"Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study","volume":"8","author":"S\u00e4vendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.951331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T09:16:12Z","timestamp":1660814172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.951331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":177,"alternative-id":["10.3389\/fendo.2022.951331"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.951331","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"article-number":"951331"}}